{"id":2729,"date":"2019-02-01T17:34:26","date_gmt":"2019-02-01T16:34:26","guid":{"rendered":"https:\/\/dewb.de\/en\/?p=2729"},"modified":"2019-02-28T10:29:21","modified_gmt":"2019-02-28T09:29:21","slug":"new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/","title":{"rendered":"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer"},"content":{"rendered":"<p><strong>Data complements previously published results showing activity of NOX-E36 in pancreatic cancer<\/strong><\/p>\n<p><strong>Berlin, Germany, February 1, 2019<\/strong>\u00a0&#8211; NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the full publication by Bartneck et al. [Cell Mol Gastroenterol Hepatol, 2019; 7:371\u2013390, <a href=\"https:\/\/www.cmghjournal.org\/article\/S2352-345X(18)30153-X\/pdf\">link<\/a>] of a series of experiments exploring the potential of CCL2 inhibition in liver cancer with mNOX-E36, a rodent version of NOXXON\u2019s human CCL2 inhibitor NOX- E36. In a mouse model of hepatocellular cancer, researchers found that treatment with mNOX-E36 inhibited the infiltration of tumor-associated macrophages, which resulted in profound changes of the tumor microenvironment, reduced pathogenic vascularization, and reduced liver tumor volume. The article was also highlighted in an accompanying editorial commentary by Avila &amp; Berasain (<a href=\"https:\/\/www.cmghjournal.org\/article\/S2352-345X(18)30165-6\/pdf\">link<\/a>).<\/p>\n<p>The preclinical results suggest that blocking the recruitment of macrophages in the liver with an anti- CCL2 molecule such as NOX-E36 is a promising mechanism for the treatment of hepatocellular cancer, which \u2013 in addition to previously published data on pancreatic cancer (Lazarus et al., Ann Surg Oncol, 2017; 24 (suppl 1): p. S100) \u2013 is the second solid tumor for which monotherapy activity of mNOX-E36 has been demonstrated. The authors conclude that \u201cthe clear link between CCR2+ macrophages and pathogenic tumor vascularization supports the exploration of combination therapies (e.g., combining CCR2 or CCL2 inhibition with conventional HCC treatment modalities), and with novel PD1-directed immunotherapies.\u201d<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2729\" data-postid=\"2729\" class=\"themify_builder_content themify_builder_content-2729 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>Data complements previously published results showing activity of NOX-E36 in pancreatic cancer<\/p>\n","protected":false},"author":3,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"Data complements previously published results showing activity of NOX-E36 in pancreatic cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-01T16:34:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-28T09:29:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"marcoscheidler\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"marcoscheidler\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\"},\"author\":{\"name\":\"marcoscheidler\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff\"},\"headline\":\"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer\",\"datePublished\":\"2019-02-01T16:34:26+00:00\",\"dateModified\":\"2019-02-28T09:29:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\",\"url\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\",\"name\":\"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2019-02-01T16:34:26+00:00\",\"dateModified\":\"2019-02-28T09:29:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff\",\"name\":\"marcoscheidler\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g\",\"caption\":\"marcoscheidler\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/","og_locale":"en_US","og_type":"article","og_title":"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"Data complements previously published results showing activity of NOX-E36 in pancreatic cancer","og_url":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2019-02-01T16:34:26+00:00","article_modified_time":"2019-02-28T09:29:21+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"marcoscheidler","twitter_card":"summary_large_image","twitter_misc":{"Written by":"marcoscheidler","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/"},"author":{"name":"marcoscheidler","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff"},"headline":"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer","datePublished":"2019-02-01T16:34:26+00:00","dateModified":"2019-02-28T09:29:21+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/","url":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/","name":"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2019-02-01T16:34:26+00:00","dateModified":"2019-02-28T09:29:21+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/new-data-published-supporting-monotherapy-activity-of-ccl2-inhibitor-nox-e36-in-an-additional-solid-tumor-type-live-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff","name":"marcoscheidler","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g","caption":"marcoscheidler"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2729"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2729"}],"version-history":[{"count":2,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2729\/revisions"}],"predecessor-version":[{"id":2734,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2729\/revisions\/2734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}